HAEMONETICS CORP — Director's Dealing 2014

Oct 24, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2014-10-22

Reporting Person: Helsel Dave (EVP, Global Manufacturing)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-10-22	Common Stock	A	3597.0	$0.0	Acquired	13617	Direct
2014-10-24	Common Stock	D	243.0	$35.44	Disposed	13374	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-10-22	Non-Qualified Stock Option (right to buy)	$34.745	A	15964.0	Acquired	2024-10-22	Common Stock (15964)	Direct
2014-10-22	Performance Shares	$0.0	A	7194.0	Acquired	2017-12-31	Common Stock (7194)	Direct

Footnotes

F1: Restricted Stock Unit Grant which vest 25% per year over 4 years following the grant date. Grant was made under 2005 Long Term Incentive Compensation Plan.

F2: Pursuant to a 10b5-1 Plan to cover tax liability for released shares.

F3: Grant to reporting person of right to buy shares of common stock exercisable in annual increments of 25 percent beginning on the first anniversary of the date of grant.

F4: Performance Share Units represent a right to receive one share of Haemonetics Corporation common stock for each Performance Stock Unit based on the performance of Haemonetics stock price relative to the Standard & Poors Health Care Equipment Index. The number of Performance Stock Units (and therefore the number of shares payable) will depend on the Company's stock price performance between October 1, 2014 and September 30, 2017. The Performance Stock Units disclosed in column 5 represent a target amount. The number of shares ultimately issued could range from none to twice the target amount in column 5. The Performance Stock Units were granted under the 2005 Haemonetics Corporation Long-Term Incentive Compensation Plan and are exempt under Rule 16b-3(d).